Genetic counselling in a national referral centre for pulmonary hypertension

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 541-552

  Girerd, Barbara ^a,b,c   Montani, David ^a,b,c   Jaïs, Xavier ^a,b,c   Eyries, Mélanie ^d   Yaici, Azzedine ^a,b,c   Sztrymf, Benjamin ^a,b,c   Savale, Laurent ^a,b,c   Parent, Florence ^a,b,c   Coulet, Florence ^d   Godinas, Laurent ^a,b,c   Lau, Edmund M ^a,b,e   Tamura, Yuichi ^a,b,c   Sitbon, Olivier ^a,b,c   Soubrier, Florent ^d   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Universite Paris Sud   (France)

^d Institute OfCardiometabolism and Nutrition   (France)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACVRL1 GENE; ADULT; ARTICLE; BMPR2 GENE; CAV 1 GENE; CONTROLLED STUDY; EIF2AK4 GENE; ENG GENE; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH CARE FACILITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; KCNK3 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RELATIVE; SMAD9 GENE; ASYMPTOMATIC DISEASE; FAMILY; FRANCE; GENETICS; MUTATION; PREIMPLANTATION GENETIC DIAGNOSIS; PROCEDURES; TERTIARY CARE CENTER;

ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BMPR2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CAV1 PROTEIN, HUMAN; CAVEOLIN 1; CELL SURFACE RECEPTOR; EIF2AK4 PROTEIN, HUMAN; ENDOGLIN; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NERVE PROTEIN; POTASSIUM CHANNEL SUBFAMILY K MEMBER 3; PROTEIN SERINE THREONINE KINASE; SMAD8 PROTEIN; SMAD9 PROTEIN, HUMAN; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

ACTIVIN RECEPTORS, TYPE II; ADULT; ANTIGENS, CD; ASYMPTOMATIC DISEASES; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CAVEOLIN 1; ENDOGLIN; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FAMILY; FEMALE; FRANCE; GENETIC COUNSELING; GENETIC TESTING; HUMANS; HYPERTENSION, PULMONARY; MALE; MUTATION; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PREIMPLANTATION DIAGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PULMONARY VENO-OCCLUSIVE DISEASE; RECEPTORS, CELL SURFACE; SMAD8 PROTEIN; TERTIARY CARE CENTERS;

EID: 84958093345     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00717-2015     Document Type: Article

References (39)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015; in press [DOI: 10.1093/eurheartj/ehv317].
3. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
4. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
5. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954; 30: 195-207.
6. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 892-896.
7. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-280.
8. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95: 2603-2606.
9. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
10. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
11. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16: 251-263.
12. Fujii M, Takeda K, Imamura T, et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999; 10: 3801-3813.
13. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D4-D12.
14. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32-S42.
15. Rosenzweig EB, Morse JH, Knowles JA, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27: 668-674.
16. Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181: 851-861.
17. Aldred MA, Machado RD, James V, et al. Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007; 176: 819-824.
18. Cogan JD, Pauciulo MW, Batchman AP, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 590-598.
19. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat 2015; 36: 1113-1127.
20. Thomson J, Machado R, Pauciulo M, et al. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. J Heart Lung Transplant 2001; 20: 149.
21. Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004; 59: 446-448.
22. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32: 1385-1389.
23. Shintani M, Yagi H, Nakayama T, et al. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46: 331-337.
24. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (Caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5: 336-343.
25. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369: 351-361.
26. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
27. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189-200.
28. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87: 220-233.
29. Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46: 65-69.
30. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
31. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
32. Laveneziana P, Montani D, Dorfmüller P, et al. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. Eur Respir J 2014; 44: 1069-1072.
33. Girerd B, Coulet F, Jaïs X, et al. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest 2015; 147: 1385-1394.
34. Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177: 1377-1383.
35. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
36. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D13-D21.
37. Frydman N, Steffann J, Girerd B, et al. Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J 2012; 39: 1534-1535.
38. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745.
39. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.